Arvinas Appoints Randy Teel as CEO 

New Haven-based biotech company Arvinas has appointed Randy Teel as its new president and CEO.  

Teel previously served as the Arvinas’ chief business officer. He will now also become a member of the company’s board of directors.  

The company chose Teel after a comprehensive search, citing his strategic leadership in advancing corporate growth and his ability to foster industry partnerships.

“Randy brings a strategic vision, a deep understanding of the company’s scientific and operational foundation, and an ability to understand and address the priorities of multiple stakeholders,” said newly elected Arvinas board chair Dr. Briggs Morrison. 

Teel joined Arvinas in 2018. He was part of the company’s initial public offering  and transition to a public, clinical-stage biotech firm. 

‘Pivotal Moment’

Before joining Arvinas, Teel held roles at Alexion Pharmaceuticals and McKinsey & Company. 

“I am honored to step into this role at such a pivotal moment for Arvinas and to build on the strong foundation and momentum we’ve created,” said Teel.   

“I am honored to step into this role at such a pivotal moment for Arvinas.”

Arvinas’ Randy Teel

Teel succeeds John Houston, who announced his plans to retire in July 2025 after serving as president and CEO since 2017.

Houston will remain on the board and serve as a consultant for the company.  

“I’m proud of all we have accomplished together and confident that Randy will lead Arvinas to new levels of innovation and impact,” he said.